1363281-33-7

Basic information

• Product Name: 5-(3,5-difluorobenzoyl)-4,5,6,7-tetrahydro-2-(phenoxymethyl)-oxazolo[5,4-c]pyridine
• Synonyms: 5-(3,5-difluorobenzoyl)-4,5,6,7-tetrahydro-2-(phenoxymethyl)-oxazolo[5,4-c]pyridine
• CAS NO: 1363281-33-7
• Molecular Weight: 370.355
• Mol File: 1363281-33-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-(3,5-difluorobenzoyl)-4,5,6,7-tetrahydro-2-(phenoxymethyl)-oxazolo[5,4-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(3,5-difluorobenzoyl)-4,5,6,7-tetrahydro-2-(phenoxymethyl)-oxazolo[5,4-c]pyridine(1363281-33-7)
• EPA Substance Registry System: 5-(3,5-difluorobenzoyl)-4,5,6,7-tetrahydro-2-(phenoxymethyl)-oxazolo[5,4-c]pyridine(1363281-33-7)

Safety Data

• Hazardous Substances Data: 1363281-33-7(Hazardous Substances Data)

Upstream product

• 1363287-26-6 ethyl 3-oxo-4-[(2-phenoxyacetyl)amino]piperidine-1-carboxylate 
• 1363286-25-2 ethyl 2-(phenoxymethyl)-6,7-dihydro-4H-oxazolo[5,4-c]pyridine-5-carboxylate 
• 1363286-22-9 6,7-dihydro-2-(hydroxymethyl)-oxazolo[5,4-c]pyridine-5(4H)-carboxylic acid ethyl ester 
• 1363286-19-4 2-formyl-6,7-dihydro-oxazolo[5,4-c]pyridine-5(4H)-carboxylic acid ethyl ester 
• 1363286-16-1 2-(1,2-dihydroxy-2-phenylethyl)-6,7-dihydro-oxazolo[5,4-c]pyridine-5(4H)-carboxylic acid ethyl ester 
• 1363286-13-8 6,7-dihydro-2-[(E)-2-phenylethenyl]-oxazolo[5,4-c]pyridine-5(4H)-carboxylic acid ethyl ester 
• 29976-53-2 N-ethoxycarbonyl-4-piperidone 
• 455-40-3 3,5-difluorobenzoic acid 
• 1363286-28-5 2-(phenoxymethyl)-4,5,6,7-tetrahydrooxazolo[5,4-c]pyridine 
• 86718-22-1 ethyl (3S,4R)-4-amino-3-hydroxypiperidine-1-carboxylate 
• 95629-02-0 ethyl 3-bromo-4-oxo-1-piperidinecarboxylate 

Relevant articles and documents

BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS

In one aspect, the invention relates to novel bicyclic oxazole and thiazole compounds which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 ("mGluR5"); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions; and methods for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.